The prescribing information for two respiratory syncytial virus (RSV) vaccines will now include a warning for the increased ...

Tempus AI is projected to achieve 30% YoY top line growth in Q4 2024 as presented in its preliminary results. Click here to ...

A small, but positive, randomized double-blind trial of baricitinib for PMR is the first in patients with the condition to ...

Holford covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, GlaxoSmithKline, and Pfizer. According to TipRanks, Holford has an average return of 10.7% and a 55.13% success rate on ...

First-line treatment with targeted therapies plus chemotherapy offered overall response benefits in BRAF V600E-mutant ...

LONDON - GlaxoSmithKline PLC (LSE/NYSE: NYSE:GSK) announced today that the European Medicines Agency (EMA) has begun ...

GlaxoSmithKline (GSK – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Graham Parry from ...

At-home DNA testing is no longer in high demand — and critics have raised concerns about unreliable tests and privacy.

Ana Botin, executive chair of Spanish bank Santander has denied reports that the company is considering leaving the British ...

The MRHA, which overseas the safety of medicines, vaccines and healthcare devices, was accused of not acting fast enough when ...

DelveInsight's 'Tuberculosis Pipeline Insight 2025' report provides comprehensive global coverage of pipeline tuberculosis ...

We recently published a list of 12 Undervalued Defensive Stocks for 2025. In this article, we are going to take a look at ...